A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)

A Clinical Trial to Evaluate the Immunogenicity Bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in Healthy Population Aged 18-59 Years

This is a randomized, double-blind , non-inferiority design study, to evaluate the Immunogenicity bridging between different manufacture scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in healthy population aged 18-59 years with immunization procedures 0, 21, 42 days .

Study Overview

• Status: Completed
• Conditions: COVID-19; SARS-CoV-2 Pneumonia
• Intervention / Treatment: Biological: Recombinant COVID-19 vaccine (Sf9 cell)

Detailed Description

This is a randomized, double-blind , non-inferiority design study, to evaluate the Immunogenicity bridging between different manufacture scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in healthy population aged 18-59 years with vaccination course 0, 21, 42 days. 892 subjects aged 18-59 years are recruited and randomly inoculated in a 1:1 ratio from a pilot or commercial batch of Recombinant COVID-19 Vaccine (Sf9 Cell).

• Study Type: Interventional
• Enrollment (Actual): 1000
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Huai'an, Jiangsu, China, 210009
      • Jiangsu Provincial Center for Disease Control and Prevention

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Subjects aged from 18-59 years.
• Signed informed consent forms of the subjects have been obtained.
• Able and willing to comply with the requirements of the clinical trial protocol and able to complete approximately 8 months of study follow-up.
• Axillary temperature < 37.3℃. Subjects who fulfill all the required conditions for receiving the candidate vaccine as established by medical history and physical examination and determined by investigators.

Exclusion Criteria:

• Positive SARS-CoV-2 antibodies (IgG or IgM) screening results.
• Positive SARS-CoV-2 Antigen screening results.
• History of COVID-19 vaccination.
• Previously diagnosed with COVID-19 infection.
• History of HIV infection.
• History or family history of convulsion, epilepsy, encephalopathy and psychosis.
• Allergy to any component of the candidate vaccine, severe allergy to vaccine in the past, and history of allergy.
• Women with positive urine pregnancy test results, pregnant, lactating women, or women who have a pregnancy plan during the study.
• Patients with acute febrile diseases and infectious diseases.
• Patients with a history of SARS.
• Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension that cannot be controlled by drugs, etc.
• Serious chronic diseases or progressive stage of a disease that cannot be steadily controlled, such as asthma, diabetes mellitus, thyroid disease, etc.
• Congenital or acquired angioedema/angioneurotic edema.
• Urticaria 1 year before receiving the candidate vaccine.
• Asplenia or functional asplenia.
• Thrombocytopenia or other coagulation disorders (which may contraindicate intramuscular injection).
• Fear of needles.
• Any immunosuppressant, antiallergic therapy, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months.
• Blood products within 4 months prior to receiving the candidate vaccine.
• Any other investigational medicine(s) within 1 month prior to the candidate vaccine.
• Any live attenuated vaccine within 1 month prior to the candidate vaccine.
• Any subunit vaccine or inactivated vaccine within 14 days prior to the candidate vaccine.
• Receiving antituberculosis treatment.
• Medical, psychological, social or other factors, which in the discretion of the investigators fail to meet the requirements in the trial protocol or affect the subjects to sign the ICFs.

Exclusion criteria for the second/third dose:

In this trial, the second/third vaccination may be stopped in some cases. They include systemic allergic reaction, severe hypersensitivity, or intolerable Grade 3 or above ARs after the previous dose of vaccine. If these reactions occur, the subjects should not continue to receive the second/third vaccination.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pilot batch; Three doses of Recombinant COVID-19 vaccine (Sf9 cell) at the schedule of day 0, 21，42.	Biological: Recombinant COVID-19 vaccine (Sf9 cell); This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
Active Comparator: Commercial batch; Three doses of Recombinant COVID-19 vaccine (Sf9 cell) at the schedule of day 0, 21，42.	Biological: Recombinant COVID-19 vaccine (Sf9 cell); This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence of adverse reactions(ARs).	The incidence of ARs within 7 days after each vaccination.	Day 0 to day 7
Anti-SARS-CoV-2 specific neutralizing antibodies expressed as geometric mean titer (GMT)and seroconversion rate (SCR).	The GMT and SCR of anti-SARS-CoV-2 specific neutralizing antibodies (euvirus) of the subjects on day 30 after the third vaccination.	Day 72

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence of ARs.	The incidence of ARs from Day 0 to Day 72.	Day 0 to Day 72
The incidence of adverse events (AEs).	The incidence of adverse events (AEs) from Day 0 to Day 72.	Day 0 to Day 72
The incidence of serious adverse events (SAEs).	The incidence of SAEs from day 0 through 6 months after the third vaccination.	Day 0 to 6 months after the third vaccination.
The Geometric Mean Fold Increase (GMI) of the anti-SARS-COV-2 specific neutralizing antibody.	The GMI of the anti-SARS-COV-2 specific neutralizing antibody of the subjects on day 30 after the third vaccination.	Day 72
The Geometric Mean Titre (GMT), Seroconversion Rate (SCR) and GMI of anti-SARS-COV-2 S-RBD Immunoglobulin (IgG) antibody	The GMT, SCR and GMI of anti-SARS-COV-2 S-RBD IgG antibody of the subjects on day 30 after the third vaccination	Day 72

Collaborators and Investigators

• Sponsor: WestVac Biopharma Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): July 20, 2022
• Primary Completion (Actual): March 11, 2023
• Study Completion (Actual): December 30, 2023

Study Registration Dates

• First Submitted: February 13, 2022
• First Submitted That Met QC Criteria: July 19, 2022
• First Posted (Actual): July 20, 2022

Study Record Updates

• Last Update Posted (Actual): April 24, 2024
• Last Update Submitted That Met QC Criteria: April 23, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: JSVCT141

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No